Top

Published in:

Open Access 01-12-2022 | Mood Disorders | Research

Serum short-chain fatty acids and its correlation with motor and non-motor symptoms in Parkinson’s disease patients

Authors: Gang Wu, Zhengli Jiang, Yaling Pu, Shiyong Chen, Tingling Wang, Yajing Wang, Xiaoping Xu, Shanshan Wang, Minya Jin, Yangyang Yao, Yang Liu, Shaofa Ke, Suzhi Liu

Published in: BMC Neurology | Issue 1/2022

Abstract

Background

Parkinson’s disease (PD) is associated with enteric nervous system dysfunction and gut microbiota dysbiosis. Short-chain fatty acids (SCFAs), derived from gut microbiota, are supposed to anticipate PD pathogenesis via the pathway of spinal cord and vagal nerve or the circulatory system. However, the serum concentration of SCFAs in PD patients is poorly known. This study aims to investigate the exact level of SCFAs in PD patients and its correlation with Parkinson’s symptoms.

Methods

50 PD patients and 50 healthy controls were recruited, and their demographic and clinical characteristics were collected. The serum concentration of SCFAs was detected using a gas chromatography-mass spectrometer. SCFAs were compared between PD and control groups. The correlation between serum SCFAs and Parkinson’s symptoms and the potential effects of medications on the serum SCFAs was analyzed.

Results

Serum propionic acid, butyric acid and caproic acid were lower, while heptanoic acid was higher in PD patients than in control subjects. However, only the serum level of propionic acid was correlated with Unified Parkinson’s Disease Rating Scale (UPDRs) part III score (R = -0.365, P = 0.009), Mini-mental State Examination (MMSE) score (R = -0.416, P = 0.003), and Hamilton Depression Scale (HAMD) score (R = 0.306, P = 0.03). There was no correlation between other serum SCFAs and motor complications. The use of trihexyphenidyl or tizanidine increased the serum concentration of propionic acid.

Conclusions

Serum SCFAs are altered in PD patients, and the decrease of serum propionic acid level is correlated with motor symptoms, cognitive ability and non-depressed state. Thus, the gut microbial-derived SCFAs potentially affect Parkinson’s symptoms through the blood circulation. Propionic acid supplementation might ameliorate motor and non-motor symptoms of PD patients, although clinical trials are needed to test this hypothesis.

Available only for authorised users

Koh A, De Vadder F, Kovatcheva-Datchary P, Bäckhed F. From dietary fiber to host physiology: short-chain fatty acids as key bacterial metabolites. Cell. 2016;165(6):1332–45. https://doi.org/10.1016/j.cell.2016.05.041.CrossRefPubMed

Morrison DJ, Preston T. Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism. Gut Microbes. 2016;7(3):189–200. https://doi.org/10.1080/19490976.2015.1134082.CrossRefPubMedPubMedCentral

Yang D, Zhao D, Ali Shah SZ, Wu W, Lai M, Zhang X, et al. The role of the gut microbiota in the pathogenesis of Parkinson's disease. Front Neurol. 2019;10:1155. https://doi.org/10.3389/fneur.2019.01155.CrossRefPubMedPubMedCentral

Keshavarzian A, Green SJ, Engen PA, Voigt RM, Naqib A, Forsyth CB, et al. Colonic bacterial composition in Parkinson's disease. Mov Disord. 2015;30(10):1351–60. https://doi.org/10.1002/mds.26307.CrossRefPubMed

Qian Y, Yang X, Xu S, Wu C, Song Y, Qin N, et al. Alteration of the fecal microbiota in Chinese patients with Parkinson’s disease. Brain Behav Immun. 2018;70:194–202. https://doi.org/10.1016/j.bbi.2018.02.016.CrossRefPubMed

Baldini F, Hertel J, Sandt E, Thinnes CC, Neuberger-Castillo L, Pavelka L, et al. Parkinson’s disease-associated alterations of the gut microbiome predict disease-relevant changes in metabolic functions. BMC Biol. 2020;18:1:62. https://doi.org/10.1186/s12915-020-00775-7.CrossRef

Scheperjans F, Aho V, Pereira P, Koskinen K, Paulin L, Pekkonen E, et al. Gut microbiota are related to Parkinson's disease and clinical phenotype. Mov Disord. 2015;30(3):350–8.CrossRef

Ren T, Gao Y, Qiu Y, Jiang S, Zhang Q, Zhang J, et al. Gut Microbiota Altered in Mild Cognitive Impairment Compared With Normal Cognition in Sporadic Parkinson's Disease. Front Neurol. 2020;11:137. https://doi.org/10.3389/fneur.2020.00137.CrossRefPubMedPubMedCentral

Unger MM, Spiegel J, Dillmann KU, Grundmann D, Philippeit H, Bürmann J, et al. Short chain fatty acids and gut microbiota differ between patients with Parkinson's disease and age-matched controls. Parkinsonism Relat Disord. 2016;32:66–72. https://doi.org/10.1016/j.parkreldis.2016.08.019.CrossRefPubMed

10.

Cirstea MS, Yu AC, Golz E, Sundvick K, Kliger D, Radisavljevic N, et al. Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease. Mov Disord. 2020;35(7):1208–17. https://doi.org/10.1002/mds.28052.CrossRefPubMed

11.

Fernández J, Redondo-Blanco S, Gutiérrez-del-Río I, Miguélez EM, Villar CJ, Lombó F. Colon microbiota fermentation of dietary prebiotics towards short-chain fatty acids and their roles as anti-inflammatory and antitumour agents: A review. J Funct Foods. 2016;25:511–22. https://doi.org/10.1016/j.jff.2016.06.032.CrossRef

12.

Sampson TR, Debelius JW, Thron T, Janssen S, Shastri GG, Ilhan ZE, et al. Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson's Disease. Cell. 2016;167(6):1469–80.e12. https://doi.org/10.1016/j.cell.2016.11.018.CrossRefPubMedPubMedCentral

13.

Mulak A. A controversy on the role of short-chain fatty acids in the pathogenesis of Parkinson's disease. Mov Disord. 2018;33(3):398–401. https://doi.org/10.1002/mds.27304.CrossRefPubMed

14.

Hou YF, Shan C, Zhuang SY, Zhuang QQ, Ghosh A, Zhu KC, et al. Gut microbiota-derived propionate mediates the neuroprotective effect of osteocalcin in a mouse model of Parkinson's disease. Microbiome. 2021;9(1):34. https://doi.org/10.1186/s40168-020-00988-6.CrossRefPubMedPubMedCentral

15.

Group of Parkinson's Disease and Movement Disorders NBoCMAPCoPsDaMDoNBoCPA. Diagnostic criteria of Parkinson's disease in China (2016 edition). Chin J Neurol. 2016;49(4):268–71. https://doi.org/10.3760/cma.j.issn.1006-7876.2016.04.002.CrossRef

16.

Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord. 2010;25(15):2649–53. https://doi.org/10.1002/mds.23429.CrossRefPubMed

17.

Nair AT, Ramachandran V, Joghee NM, Antony S, Ramalingam G. Gut Microbiota Dysfunction as Reliable Non-invasive Early Diagnostic Biomarkers in the Pathophysiology of Parkinson’s Disease: A Critical Review. J Neurogastroenterol Motil. 2018;24(1):30–42. https://doi.org/10.5056/jnm17105.CrossRefPubMedPubMedCentral

18.

Chapelet G, Leclair-Visonneau L, Clairembault T, Neunlist M, Derkinderen P. Can the gut be the missing piece in uncovering PD pathogenesis? Parkinsonism Relat Disord. 2019;59:26–31. https://doi.org/10.1016/j.parkreldis.2018.11.014.CrossRefPubMed

19.

Yano Jessica M, Yu K, Donaldson Gregory P, Shastri Gauri G, Ann P, Ma L, et al. Indigenous Bacteria from the Gut Microbiota Regulate Host Serotonin Biosynthesis. Cell. 2015;161(2):264–76. https://doi.org/10.1016/j.cell.2015.02.047.CrossRefPubMedPubMedCentral

20.

Martin CR, Osadchiy V, Kalani A, Mayer EA. The Brain-Gut-Microbiome Axis. Cell Mol Gastroenterol Hepatol. 2018;6(2):133–48. https://doi.org/10.1016/j.jcmgh.2018.04.003.CrossRefPubMedPubMedCentral

21.

Chen T, Long W, Zhang C, Liu S, Zhao L, Hamaker BR. Fiber-utilizing capacity varies in Prevotella- versus Bacteroides-dominated gut microbiota. Sci Rep. 2017;7(1):2594. https://doi.org/10.1038/s41598-017-02995-4.CrossRefPubMedPubMedCentral

22.

Powers KM, Smith-Weller T, Franklin GM, Longstreth WT, Swanson PD, Checkoway H. Parkinson’s disease risks associated with dietary iron, manganese, and other nutrient intakes. Neurology. 2003;60(11):1761–6. https://doi.org/10.1212/01.Wnl.0000068021.13945.7f.CrossRefPubMed

23.

Palavra NC, Lubomski M, Flood VM, Davis RL, Sue CM. Increased Added Sugar Consumption Is Common in Parkinson's Disease. Frontiers. Nutrition. 2021;8:207. https://doi.org/10.3389/fnut.2021.628845.CrossRef

24.

Baert F, Matthys C, Mellaerts R, Lemaître D, Vlaemynck G, Foulon V. Dietary Intake of Parkinson's Disease Patients. Front Nutr. 2020;7:105. https://doi.org/10.3389/fnut.2020.00105.CrossRefPubMedPubMedCentral

25.

Shin C, Lim Y, Lim H, Ahn TB. Plasma Short-Chain Fatty Acids in Patients With Parkinson's Disease. Mov Disord. 2020;35(6):1021–7. https://doi.org/10.1002/mds.28016.CrossRefPubMed

26.

Ostendorf F, Metzdorf J, Gold R, Haghikia A, Tönges L. Propionic Acid and Fasudil as Treatment Against Rotenone Toxicity in an In Vitro Model of Parkinson's Disease. Molecules. 2020;25(11). https://doi.org/10.3390/molecules25112502.

27.

Hoyles L, Snelling T, Umlai UK, Nicholson JK, Carding SR, Glen RC, et al. Microbiome-host systems interactions: protective effects of propionate upon the blood-brain barrier. Microbiome. 2018;6(1):55. https://doi.org/10.1186/s40168-018-0439-y.CrossRefPubMedPubMedCentral

28.

Guan J, Pavlovic D, Dalkie N, Waldvogel HJ, O'Carroll SJ, Green CR, et al. Vascular degeneration in Parkinson's disease. Brain Pathol. 2013;23(2):154–64. https://doi.org/10.1111/j.1750-3639.2012.00628.x.CrossRefPubMed

29.

Pena L, Burton BK. Survey of health status and complications among propionic acidemia patients. Am J Med Genet A. 2012;158a(7):1641–6. https://doi.org/10.1002/ajmg.a.35387.CrossRefPubMed

30.

Pettenuzzo LF, Schuck PF, Fontella F, Wannmacher CM, Wyse AT, Dutra-Filho CS, et al. Ascorbic acid prevents cognitive deficits caused by chronic administration of propionic acid to rats in the water maze. Pharmacol Biochem Behav. 2002;73(3):623–9. https://doi.org/10.1016/s0091-3057(02)00856-0.CrossRefPubMed

31.

Wu M, Tian T, Mao Q, Zou T, Zhou CJ, Xie J, et al. Associations between disordered gut microbiota and changes of neurotransmitters and short-chain fatty acids in depressed mice. Transl Psychiatry. 2020;10(1):350. https://doi.org/10.1038/s41398-020-01038-3.CrossRefPubMedPubMedCentral

32.

Lobzhanidze G, Lordkipanidze T, Zhvania M, Japaridze N, MacFabe DF, Pochkidze N, et al. Effect of propionic acid on the morphology of the amygdala in adolescent male rats and their behavior. Micron. 2019;125:102732. https://doi.org/10.1016/j.micron.2019.102732.CrossRefPubMed

33.

Song W, Guo X, Chen K, Chen X, Cao B, Wei Q, et al. The impact of non-motor symptoms on the Health-Related Quality of Life of Parkinson's disease patients from Southwest China. Parkinsonism Relat Disord. 2014;20(2):149–52. https://doi.org/10.1016/j.parkreldis.2013.10.005.CrossRefPubMed

34.

Hill-Burns EM, Debelius JW, Morton JT, Wissemann WT, Lewis MR, Wallen ZD, et al. Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome. Mov Disord. 2017;32(5):739–49. https://doi.org/10.1002/mds.26942.CrossRefPubMedPubMedCentral

35.

Jameson KG, Olson CA, Kazmi SA, Hsiao EY. Toward Understanding Microbiome-Neuronal Signaling. Mol Cell. 2020;78(4):577–83. https://doi.org/10.1016/j.molcel.2020.03.006.CrossRefPubMed

36.

Wei Q, Wang H, Tian Y, Xu F, Chen X, Wang K. Reduced serum levels of triglyceride, very low density lipoprotein cholesterol and apolipoprotein B in Parkinson's disease patients. PLoS One. 2013;8(9):e75743. https://doi.org/10.1371/journal.pone.0075743.CrossRefPubMedPubMedCentral

37.

Guo X, Song W, Chen K, Chen X, Zheng Z, Cao B, et al. The serum lipid profile of Parkinson's disease patients: a study from China. Int J Neurosci. 2015;125(11):838–44. https://doi.org/10.3109/00207454.2014.979288.CrossRefPubMed

38.

Fu X, Wang Y, He X, Li H, Liu H, Zhang X. A systematic review and meta-analysis of serum cholesterol and triglyceride levels in patients with Parkinson's disease. Lipids Health Dis. 2020;19:1:97. https://doi.org/10.1186/s12944-020-01284-w.CrossRef

39.

Saedi S, Hemmati-Dinarvand M, Barmaki H, Mokhtari Z, Musavi H, Valilo M, et al. Serum lipid profile of Parkinson's disease patients: A study from the Northwest of Iran. Caspian J Intern Med. 2021;12(2):155–61. https://doi.org/10.22088/cjim.12.2.155.CrossRefPubMedPubMedCentral

Title: Serum short-chain fatty acids and its correlation with motor and non-motor symptoms in Parkinson’s disease patients
Authors: Gang Wu
Zhengli Jiang
Yaling Pu
Shiyong Chen
Tingling Wang
Yajing Wang
Xiaoping Xu
Shanshan Wang
Minya Jin
Yangyang Yao
Yang Liu
Shaofa Ke
Suzhi Liu
Publication date: 01-12-2022
Publisher: BioMed Central
Keywords: Mood Disorders
Affective Disorder
Respiratory Microbiota
Parkinson's Disease
Published in: BMC Neurology / Issue 1/2022
Electronic ISSN: 1471-2377
DOI: https://doi.org/10.1186/s12883-021-02544-7

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Serum short-chain fatty acids and its correlation with motor and non-motor symptoms in Parkinson’s disease patients

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2022

Current physical therapy practice and implementation factors regarding the evidence-based ‘Rehabilitation of Mobility after Stroke (ReMoS)’ guideline in Germany: a cross-sectional online survey

Advanced MRI features of intraventricular inflammatory myofibroblastic tumor: a case report

Godtfredsen syndrome – recurrent clival chondrosarcoma with 6 years follow up: a case report and literature review

Fasciculation intensity and limb dominance in amyotrophic lateral sclerosis: a muscle ultrasonographic study

Correction: Optimizing Prehospital Stroke Systems of Care-Reacting to Changing Paradigms (OPUS-REACH): a pragmatic registry of large vessel occlusion stroke patients to create evidence-based stroke systems of care and eliminate disparities in access to stroke care

Individualized combination therapies based on whole-exome sequencing displayed significant clinical benefits in a glioblastoma patient with secondary osteosarcoma: case report and genetic characterization